title: Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma.
abstract: There is evidence to suggest that CDC25B phosphatase is an oncogenic protein. To elucidate the role of CDC25B in colorectal carcinoma, we examined the expression of CDC25B at the mRNA and protein levels. Reverse transcription-PCR assay indicated that CDC25B was overexpressed in tumor tissues relative to normal mucosa in 6 of 10 cases. Using immunohistochemistry, we identified high expression of CDC25B in 77 of 181 colorectal cases (43%). Univariate analysis showed that high expression was a significant predictor for poor prognosis compared with low expression (5-year survival rate; 59% versus 82%, respectively; P < 0.0001). Multivariate analysis indicated that CDC25B was an independent prognostic marker (risk ratio for death, 3.7; P < 0.0001) even after controlling for various factors such as lymph node metastasis, tumor size, degree of differentiation, and depth of invasion. Furthermore, the level of CDC25B expression clearly predicted the outcome of patients with Dukes' B and Dukes' C tumors. On the other hand, CDC25A mRNA was overexpressed in 9 of 10 colorectal cancer cases, and immunohistochemistry for CDC25A showed high expression in 52 of 111 cases (47%), but no significant correlation with prognosis. Our findings suggest that CDC25B is a novel independent prognostic marker of colorectal carcinoma and that it may be clinically useful for selecting patients who could benefit from adjuvant therapy.
authors.affiliation: Department of Surgery II, Osaka University Medical School, Suita City, Japan.
authors.forename: I
authors.initials: I
authors.lastname: Takemasa
authors.forename: H
authors.initials: H
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Sekimoto
authors.forename: M
authors.initials: M
authors.lastname: Ohue
authors.forename: S
authors.initials: S
authors.lastname: Noura
authors.forename: Y
authors.initials: Y
authors.lastname: Miyake
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
authors.forename: T
authors.initials: T
authors.lastname: Aihara
authors.forename: N
authors.initials: N
authors.lastname: Tomita
authors.forename: Y
authors.initials: Y
authors.lastname: Tamaki
authors.forename: I
authors.initials: I
authors.lastname: Sakita
authors.forename: N
authors.initials: N
authors.lastname: Kikkawa
authors.forename: N
authors.initials: N
authors.lastname: Matsuura
authors.forename: H
authors.initials: H
authors.lastname: Shiozaki
authors.forename: M
authors.initials: M
authors.lastname: Monden
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D015153:Blotting, Western; D002277:Carcinoma / Q000175:diagnosis* / Q000201:enzymology* / Q000401:mortality; D018797:Cell Cycle Proteins / Q000096:biosynthesis*; D003106:Colon / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000401:mortality; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D015999:Multivariate Analysis; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020687:cdc25 Phosphatases / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D019394:Ki-67 Antigen; D012333:RNA, Messenger; C517004:CDC25A protein, human; C517008:CDC25B protein, human; D020687:cdc25 Phosphatases